Sneha Phadke1, Alexandra Thomas1, Limin Yang2, Catherine Moore3, Chang Xia4, Mary C Schroeder5. 1. Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA. 2. Department of Radiology, Carver College of Medicine, University of Iowa, Iowa City, IA. 3. Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA; Oncology Specialists of Charlotte, Charlotte, NC. 4. Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA; ProMedica Hematology/Oncology Associates, Sylvania, OH. 5. Division of Health Services Research, Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, IA. Electronic address: mary-schroeder@uiowa.edu.
Abstract
BACKGROUND: Use of breast magnetic resonance imaging (MRI) for screening and local staging of breast cancer has increased. With this, questions have emerged regarding the management and effect of extramammary findings (EMFs) reported on breast MRI. PATIENTS AND METHODS: Breast MRI studies performed between January 1, 2007 and December 31, 2012 at the University of Iowa were analyzed. Data were collected regarding number and location of EMFs, characteristics of the patients who had a breast MRI, and time to first treatment among the patients who had a breast MRI for stage I-III breast cancer. RESULTS: During the study period, 1305 breast MRIs were obtained in 772 women. An EMF was found in 140 studies (10.7%) and 113 women (14.6%). EMFs were more likely in MRIs of older patients (50 vs. 54 years, P = .004) and postmenopausal women (P = .001). Anatomically, most EMFs were seen in the liver (89 of 140) or bone (21 of 140). Eight women (0.6%) had an EMF on breast MRI that led to upstaging to stage IV breast cancer. For patients with stage I-III breast cancer, the finding of an EMF on breast MRI did not affect time to initial cancer treatment (13 vs. 14 days; P = .586). CONCLUSION: EMFs on breast MRI are seen with some frequency and occur more commonly in older, postmenopausal women. In our study, most EMFs were benign and did not affect patient outcome with regard to upstaging to stage IV disease or time to cancer treatment. A very small portion of studies revealed subclinical advanced breast cancer.
BACKGROUND: Use of breast magnetic resonance imaging (MRI) for screening and local staging of breast cancer has increased. With this, questions have emerged regarding the management and effect of extramammary findings (EMFs) reported on breast MRI. PATIENTS AND METHODS: Breast MRI studies performed between January 1, 2007 and December 31, 2012 at the University of Iowa were analyzed. Data were collected regarding number and location of EMFs, characteristics of the patients who had a breast MRI, and time to first treatment among the patients who had a breast MRI for stage I-III breast cancer. RESULTS: During the study period, 1305 breast MRIs were obtained in 772 women. An EMF was found in 140 studies (10.7%) and 113 women (14.6%). EMFs were more likely in MRIs of older patients (50 vs. 54 years, P = .004) and postmenopausal women (P = .001). Anatomically, most EMFs were seen in the liver (89 of 140) or bone (21 of 140). Eight women (0.6%) had an EMF on breast MRI that led to upstaging to stage IV breast cancer. For patients with stage I-III breast cancer, the finding of an EMF on breast MRI did not affect time to initial cancer treatment (13 vs. 14 days; P = .586). CONCLUSION: EMFs on breast MRI are seen with some frequency and occur more commonly in older, postmenopausal women. In our study, most EMFs were benign and did not affect patient outcome with regard to upstaging to stage IV disease or time to cancer treatment. A very small portion of studies revealed subclinical advanced breast cancer.
Authors: Francesco Sardanelli; Gian M Giuseppetti; Pietro Panizza; Massimo Bazzocchi; Alfonso Fausto; Giovanni Simonetti; Vincenzo Lattanzio; Alessandro Del Maschio Journal: AJR Am J Roentgenol Date: 2004-10 Impact factor: 3.959
Authors: Michael L Marinovich; Nehmat Houssami; Petra Macaskill; Francesco Sardanelli; Les Irwig; Eleftherios P Mamounas; Gunter von Minckwitz; Meagan E Brennan; Stefano Ciatto Journal: J Natl Cancer Inst Date: 2013-01-07 Impact factor: 13.506
Authors: E Warner; D B Plewes; R S Shumak; G C Catzavelos; L S Di Prospero; M J Yaffe; V Goel; E Ramsay; P L Chart; D E Cole; G A Taylor; M Cutrara; T H Samuels; J P Murphy; J M Murphy; S A Narod Journal: J Clin Oncol Date: 2001-08-01 Impact factor: 44.544
Authors: Ellen Warner; Hans Messersmith; Petrina Causer; Andrea Eisen; Rene Shumak; Donald Plewes Journal: Ann Intern Med Date: 2008-05-06 Impact factor: 25.391
Authors: Natasha K Stout; Larissa Nekhlyudov; Lingling Li; Elisabeth S Malin; Dennis Ross-Degnan; Diana S M Buist; Marjorie A Rosenberg; Marina Alfisher; Suzanne W Fletcher Journal: JAMA Intern Med Date: 2014-01 Impact factor: 21.873